GlobeNewswire

Jitterbit Enterprise iPaaS Platform Now GDPR Ready

Dela

Leading Enterprise iPaaS Provider Announces Compliance With Rigorous Data Privacy and Security Standards to Enable Customers to Continue Operations in Europe Without Interruption

ALAMEDA, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Jitterbit, the API transformation company, today announced that its Harmony enterprise integration platform-as-a-service (iPaaS) now meets the new General Data Protection Regulation (GDPR) requirements going into effect May 25. Jitterbit's Harmony platform surpasses the security requirements mandated by GDPR for protecting personal data, and fulfills new requirements for consent to share any data collected from its customers in the European Union (EU), as well as for customers to access and erase their data. More importantly, Jitterbit's Harmony platform uses clear and easy-to-understand workflows to track the path of GDPR data, helping enterprise clients across the globe ensure that they maintain GDPR compliance as they connect systems and applications that store data from their own customers in the EU.

GDPR mandates that organizations must follow strict rules for how they collect, share, and protect personal data of citizens of the European Union. The impact of this mandate reaches beyond the EU, because most global companies located outside of the EU collect or store data for EU citizen customers. Connecting customer data across multiple systems is crucial to orchestrate today's best of breed applications and services, but this streamlined data-sharing and automation are complicated by new GDPR requirements. For example, if an EU citizen opts to delete personal data shared with a company through one application, that company must ensure that the data is also removed from all other integrated applications and systems that had access to it.

Jitterbit's enterprise iPaaS enables companies to track GDPR-sensitive data across multiple systems, by ensuring that personal data can be tracked and accounted for at all times. Because Jitterbit users can granularly select the specific records and types of data to exchange between different applications or services, and get a clear visualization of how data flows across the enterprise, Jitterbit makes it easier for companies to comply with some of the more complex GDPR requirements.

Aspects of Jitterbit Harmony platform that support GDPR compliance include:

  • Privacy-by-design and privacy-by-default principles incorporated into workflows
  • Synchronization of customers' opt-in consent between various systems
  • Easy auditing of data processing workflows to confirm limits on data collection and management of personal data usage with regard to stated preferences
  • Updated process for cross-border data transfers and restrictions
  • Fully independent clouds for EU and non-EU geographies to ensure data on the platform will not be exposed across regions without client authorization

Finally, Jitterbit has appointed Henk Adriaans and Damon Pugh to serve as data privacy officers for the EU and US, respectively. These new roles will oversee Jitterbit's company-wide and regional data storage policies and processes and respond to customers' data requests and inquiries.

With the GDPR compliance date of May 25 quickly approaching, many organizations are still formulating plans to address GDPR privacy regulations. With so many components to consider in so little time, Jitterbit will host a webinar Friday, April 20, at 11 a.m. CET/5 a.m. EST, to help organizations achieve and maintain compliance. Jitterbit experts will highlight five key elements for a sustainable GDPR strategy and how Jitterbit's enterprise iPaaS solution helps businesses achieve compliance.

Please visit the Jitterbit website to register for the webinar.

About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit API integration platform enables companies to quickly connect SaaS, on-premise, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com and follow @Jitterbit on Twitter.

Media Contact:
Nathaniel Hawthorne
BOCA Communications
661.965.0407
jitterbit@bocacommunications.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Jitterbit, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum